all press releases

  • 07/10/18
    IRVING, Texas--(BUSINESS WIRE)--Top oncology stakeholders from across the health care industry are set to meet this week at the MedCity CONVERGE event July 11-12 in Philadelphia. Steven Lucio, associate vice president, pharmacy services, at Vizient will be one of the featured panelists for the session, “Promising Drugs, Pricing and Access” which will focus on the impact of increasingly expensive, novel oncology therapies on the U.S. health care market. The panel willmore...
  • 07/02/18
    IRVING, Texas--(BUSINESS WIRE)--For many years, Vizient has been helping diverse suppliers refine their business strategy to more effectively compete, prosper, and grow within the health care supply chain. Today, the company announces it is expanding its support of diverse suppliers through a new agreement with the Initiative for a Competitive Inner City (ICIC) and their Inner City Capital Connections program (ICCC). The agreement is expected to have a direct impact onmore...
  • 06/26/18
    IRVING, Texas--(BUSINESS WIRE)--Suppliers interested in showcasing their innovative technology to clinicians nationwide are encouraged to act quickly to apply to participate in the 2018 Vizient Innovative Technology Exchange. The event will take place on Thursday, October 4, 2018, at the Wynn Hotel in Las Vegas as part of the 2018 Vizient Connection Summit. The deadline to apply is Friday, July 13, 2018. The 2018 Innovative Technology Exchange ismore...
  • 06/22/18
    IRVING, Texas--(BUSINESS WIRE)--Vizient is deeply concerned that current tariffs set to go into effect on July 6, and any ensuing trade war, will have long term impacts on the cost of health care in the U.S., which is already at unsustainably high levels. Every day we work to ensure that patients have access to the best possible suppliers and services for first-rate medical care. That is why we are troubled to see that a 25% tariff will be placed on medical/more...
  • 06/15/18
    IRVING, Texas--(BUSINESS WIRE)--Vizient applauds the recent decision by The Centers for Medicare and Medicaid Services to delay its update to the Overall Hospital Star Ratings that was planned for July. This decision by CMS is supported by data that Vizient provided to the Agency related to methodology issues that negatively affect hospital ratings. Vizient’s feedback to CMS focused on specific technical details identified in the July 2018 preview reports. Themore...
  • 06/13/18
    IRVING, Texas--(BUSINESS WIRE)--Vizient, Inc. today announced its support for the Stretching Entity Resources for Vulnerable (SERV) Communities Act. This newly proposed legislation would take a number of important steps to protect and preserve the integrity of the 340B Drug Pricing Program, which is essential for safety-net hospitals that provide critical health care services to vulnerable patients and underserved communities. The SERV Act wouldmore...
  • 06/11/18
    IRVING, Texas--(BUSINESS WIRE)--Vizient, Inc. has been selected by Modern Healthcare as one of the 2018 Best Places to Work in Healthcare. The complete list of this year’s winners, in alphabetical order, is available here. Modern Healthcare will publish a special supplement featuring ranked lists of all the winners along with the October 1 issue. “Whether on the frontline or in the top office, healthcare employees witness moments that can either inspire ormore...
  • 06/08/18
    IRVING, Texas--(BUSINESS WIRE)--Vizient, Inc. is adding its support to a recent request by Federal Communication Commission Chairman Ajit Pai for an increase in funding for the Rural Health Care Program. If approved, the order would take immediate action to address the program’s significant funding shortfall and enable rural health care providers to continue offering telemedicine services. The program’s current annual funding cap is $400 million. The cap wasmore...
  • 06/05/18
    IRVING, Texas--(BUSINESS WIRE)--Vizient today applauds the U.S. Food and Drug Administration (FDA) on its announcement yesterday that it approved the first biosimilar to Neulasta (pegfilgrastim) and the overall progress in authorizing more competing versions of commonly used, high cost biologics. Vizient has long been a vocal proponent of biosimilar approval, adoption and use and has continued to provide education to encourage understanding of this developingmore...
  • 06/01/18
    IRVING, Texas--(BUSINESS WIRE)--In a letter submitted to the Food and Drug Administration on its proposed Medical Device Safety Action Plan, Vizient expressed support for the Agency’s proactive approach to cybersecurity that will enhance existing programs and processes, enable timely resolution of known safety issues, and encourage innovative technologies that are safer and more effective. Vizient has relationships with thousands of suppliers, hospitals, andmore...